Back to all studies
CompletedNCT06605599

ABBV-932 to Assess Adverse Events and Change for Bipolarity type I; Bipolarity type II

This study is completed in the United States and in Japan. It is testing ABBV-932 to Assess Adverse Events and Change for Bipolarity type I; Bipolarity type II.

BipolarityOtherFrom 18 Years to 65 Years
Need help deciding?

Ask HopeStage to review this study with me

Loading the security check...
Study ID: NCT06605599. We help you review the study, but cannot decide medical eligibility.
In plain English

Key information made simple

What is this study testing?

This study is testing whether Oral ABBV-932 may be useful for adults experiencing bipolarity.

What would participation involve?

Participants may receive Oral ABBV-932, complete questionnaires or follow-up assessments, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Japan and in the United States.

Who is it mainly for?

This study appears to be mainly for adults with bipolarity.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

What to expect

Your next step

The official record lists this AbbVie study as completed, with sites in the United States, Japan, and Puerto Rico. Participation involved oral capsules of ABBV-932 or placebo, weekly clinic visits during the 6-week treatment period, medical assessments, blood tests, side-effect checks, questionnaires, and a 4-week safety follow-up. The main fit was adults aged 18 to 65 with bipolarity type I or II, without psychotic features, who were in a current depressive episode and met the study's symptom-score requirements. Key exclusions included a positive urine drug screen, recent investigational drug use, current enrollment in another clinical study, recent use of psychoactive medication, and prior recent exposure to ABBV-932.

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: October 15, 2024
Recruitment status
Completed
Estimated enrollment
161
Sponsor
AbbVie
Sponsor type
Unknown or unclear
Study type
Other
Intervention type
Other / unclear
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Japan
Age range
From 18 Years to 65 Years
Official registry ID
NCT06605599
Official title
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder
Official source
Official registry link

Want help reviewing this study?

Loading the security check...
Study ID: NCT06605599. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Taking part may help improve understanding of your condition.

It requires regular follow-up, often through questionnaires or interviews.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring observational follow-up for people with bipolarity. Participants may complete study visits, assessments, or follow-up activities defined by the research team. It includes a comparison with placebo. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Why is the study type not clearly categorized?

The study type is not clearly categorized in the public registry. Focus on the objective, required tasks, visits, any intervention, and eligibility criteria, then ask the study team to confirm.

Who might this study be for?

This study may concern people with bipolarity; age range: From 18 Years to 65 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

The public registry does not clearly describe all participation steps. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What risks or points should I check?

The public registry does not make the main risk category clear. Ask the study team what activities are required, what could feel uncomfortable, how safety is monitored, and what happens if you want to stop. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by AbbVie, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The registry indicates that this study is completed. It may still be useful for understanding the research, but you are unlikely to be able to join. The registry lists an estimated enrollment of 161 participants.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me